Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington’s disease mice

被引:0
|
作者
Junghee Lee
Bela Kosaras
Steve J. Del Signore
Kerry Cormier
Ann McKee
Rajiv R. Ratan
Neil W. Kowall
Hoon Ryu
机构
[1] Boston University School of Medicine,Department of Neurology and Pathology
[2] VA Boston Healthcare System,Department of Neurology
[3] Beth Israel Deaconess Medical Center and Harvard Medical School,Department of Neurology
[4] Bedford VA Medical Center,undefined
[5] Weill Medical College of Cornell University,undefined
[6] Burke-Cornell Medical Research Institute,undefined
来源
Acta Neuropathologica | 2011年 / 121卷
关键词
Huntington’s disease; Mitochondria; Lipid peroxidation; 4-Hydroxy-2-nonenal (4-HNE); Neuronal survival;
D O I
暂无
中图分类号
学科分类号
摘要
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder. Oxidative damage has been associated with pathological neuronal loss in HD. The therapeutic modulation of oxidative stress and mitochondrial function using low molecular weight compounds may be an important strategy for delaying the onset and slowing the progression of HD. In the present study, we found a marked increase of 4-hydroxy-2-nonenal (4-HNE) adducts, a lipid peroxidation marker, in the caudate and putamen of HD brains and in the striatum of HD mice. Notably, 4-HNE immunoreactivity was colocalized with mutant huntingtin inclusions in the striatal neurons of R6/2 HD mice. Administration of nordihydroguaiaretic acid (NDGA), an antioxidant that functions by inhibiting lipid peroxidation, markedly reduced 4-HNE adduct formation in the nuclear inclusions of R6/2 striatal neurons. NDGA also protected cultured neurons against oxidative stress-induced cell death by improving ATP generation and mitochondrial morphology and function. In addition, NDGA restored mitochondrial membrane potential, mitochondrial structure, and synapse structure in the striatum of R6/2 mice and increased their lifespan. The present findings suggest that further therapeutic studies using NDGA are warranted in HD and other neurodegenerative diseases characterized by increased oxidative stress and altered mitochondrial function.
引用
收藏
页码:487 / 498
页数:11
相关论文
共 50 条
  • [21] Mitochondrial function in Huntington's disease: Clues for pathogenesis and prospects for treatment
    Schapira, AHV
    ANNALS OF NEUROLOGY, 1997, 41 (02) : 141 - 142
  • [22] Impact of SAPAP3 on mitochondrial function in Huntington's disease
    Coelho, Patricia
    Fao, Ligia
    Nobre, Rui
    de Almeida, Luis Pereira
    Peca, Joao
    Rego, A. Cristina
    FREE RADICAL BIOLOGY AND MEDICINE, 2021, 165
  • [23] Skeletal Muscle Characteristics and Mitochondrial Function in Huntington's Disease Patients
    Gehrig, Saskia Maria
    Petersen, Jens A.
    Frese, Sebastian
    Mueller, Sandro Manuel
    Mihaylova, Violeta
    Ligon-Auer, Maria
    Lundby, Carsten
    Toigo, Marco
    Jung, Hans H.
    MOVEMENT DISORDERS, 2017, 32 (08) : 1258 - 1259
  • [24] SIRT3, a modifier of mitochondrial function in Huntington's disease
    Naia, Luana
    Carmo, Catarina
    Campesan, Susanna
    Lopes, Carla
    Valero, Jorge
    Rosenstock, Tatiana R.
    Giorgini, Flaviano
    Cristina Rego, A.
    FREE RADICAL BIOLOGY AND MEDICINE, 2018, 120 : S17 - S17
  • [25] Increasing brain palmitoylation rescues behavior and neuropathology in Huntington disease mice
    Virlogeux, Amandine
    Scaramuzzino, Chiara
    Lenoir, Sophie
    Carpentier, Remi
    Louessard, Morgane
    Genoux, Aurelie
    Lino, Patricia
    Hinckelmann, Maria-Victoria
    Perrier, Anselme L.
    Humbert, Sandrine
    Saudou, Frederic
    SCIENCE ADVANCES, 2021, 7 (14)
  • [26] INCREASING BRAIN PALMITOYLATION RESCUES BEHAVIOR AND NEUROPATHOLOGY IN HUNTINGTON DISEASE MICE
    Auboyer, Laura
    Virlogeux, Amandine
    Scaramuzzino, Chiara
    Lenoir, Sophie
    Carpentier, Remi
    Louessard, Morgane
    Genoux, Aurelie
    Lino, Patricia
    Hinckelmann, Maria-Victoria
    Perrier, Anselm
    Humbert, Sandrine
    Saudou, Frederic
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 : A49 - A50
  • [27] Therapeutic potential of n-acetylcysteine in huntington's disease: effects on glutamate uptake and mitochondrial function in mice
    Wright, D.
    Renoir, T.
    Finkelstein, D.
    Thorburn, D.
    Francis, P.
    McGee, S.
    Gray, L.
    Hannan, A.
    JOURNAL OF NEUROCHEMISTRY, 2015, 134 : 209 - 209
  • [28] Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease
    Perez-De La Cruz, Veronica
    Elinos-Calderon, Diana
    Robledo-Arratia, Yolanda
    Medina-Campos, Omar N.
    Pedraza-Chaverri, Jose
    Ali, Syed F.
    Santamaria, Abel
    BEHAVIOURAL BRAIN RESEARCH, 2009, 199 (02) : 210 - 217
  • [29] Mitochondrial Dysfunction in Huntington's Disease
    Carmo, Catarina
    Naia, Luana
    Lopes, Carla
    Cristina Rego, A.
    POLYGLUTAMINE DISORDERS, 2018, 1049 : 59 - 83
  • [30] SELECTIVE NEURODEGENERATION, NEUROPATHOLOGY AND SYMPTOM PROFILES IN HUNTINGTON'S DISEASE
    Waldvogel, Henry J.
    Thu, Doris
    Hogg, Virginia
    Tippett, Lynette
    Faull, Richard L. M.
    TANDEM REPEAT POLYMORPHISMS: GENETIC PLASTICITY, NEURAL DIVERSITY AND DISEASE, 2012, 769 : 141 - 152